Argenx
Organization
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. The company focuses on the development of antibody therapies for the treatment of autoimmune diseases and cancer, with a primary emphasis on orphan drugs.
What experts have said about Argenx
1 statement · 1 positive
Argenx shares rose by as much as 10%.
“shares up as much as 10%.”
Open the episode · Fresnillo AstraZeneca Climbs, Argenx SurgesListen at 3:00
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
3 episodes featuring Argenx
Stock Movers
European miners rise as drug trials reshape pharma stocks
The episode connects commodity prices, clinical-trial risk, and drone regulation to sharp moves across European and technology-linked companies.
Aug 17, 2026 · 6 min
Stock Movers
European shares split across drugs, copper and biotech
The episode shows how clinical setbacks, strategic access to copper and trial data can move major European stocks in sharply different directions.
Aug 17, 2026 · 6 min
Stock Movers
Argenx buys Forte Biosciences for billions as media merger talks stall
A multi-billion-dollar biotech buyout and regulatory roadblocks in media entertainment signal shifting strategies in corporate consolidation.
Jul 27, 2026 · 6 min